Pfizer collaborates with Arvinas for breast cancer treatment ARV-471

By NS Healthcare Staff Writer

23 Jul 21

ARV-471 is currently in Phase 2 studies for the treatment of patients with locally advanced or metastatic ER+/HER2-…

PharmaceuticalsPartnerships and Licensing Agreements

Novartis to pay $178m to Plexxikon over patent infringement case

By NS Healthcare Staff Writer

23 Jul 21

The jury found that the Novartis failed to prove that patents were invalid and concluded that the infringement…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Biovac teams up with Pfizer and BioNTech to produce Covid-19 vaccine in Africa

By NS Healthcare Staff Writer

22 Jul 21

Pfizer and BioNTech will immediately start technical transfer, on-site development and equipment installation activities

PharmaceuticalsPartnerships and Licensing Agreements

AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals

By NS Healthcare Staff Writer

22 Jul 21

With the acquisition, AstraZeneca now has an enhanced presence in rare diseases and immunology fields, using Alexion’s complement-biology…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Octapharma gets FDA nod for Octagam 10% to treat adult dermatomyositis

By NS Healthcare Staff Writer

21 Jul 21

The US FDA approval of Octagam is based on positive data from the Phase 3 ProDERM Study in…

PharmaceuticalsRegulation

FDA approves Sanofi’s all-oral treatment for sleeping sickness

By NS Healthcare Staff Writer

20 Jul 21

Sanofi has developed the drug under the partnership with DNDi, and the National Sleeping Sickness Programmes of the…

PharmaceuticalsRegulation

US states to reveal $26bn opioid settlement with J&J, others

By NS Healthcare Staff Writer

20 Jul 21

Drug distributors McKesson, Cardinal Health and AmerisourceBergen would jointly pay $21bn, while J&J alone would pay $5bn

PharmaceuticalsRegulation

Merck gets US FDA approval for Vaxneuvance to prevent IPD

By NS Healthcare Staff Writer

19 Jul 21

Vaxneuvance triggered superior immune responses for serotypes 3, 22F and 33F compared to Merck’s 13-valent pneumococcal vaccine PCV13

PharmaceuticalsRegulation

GSK plans for new biotechnology and life science campus in UK

By NS Healthcare Staff Writer

19 Jul 21

The company aims to secure up to £400m in new private investment and create up to 5,000 new…

PharmaceuticalsManufacturing

Merck, Universal partner to produce paediatric treatment for schistosomiasis

By NS Healthcare Staff Writer

16 Jul 21

The new drug is currently being tested in a Phase 3 clinical trial in Kenya and Côte d’Ivoire

PharmaceuticalsManufacturing